Conceivable Life Sciences has closed a $50 million Series A round, led by Advance Venture Partners, to accelerate the rollout of its AI-driven, automated IVF laboratory platform. The latest raise brings the New York firm’s total funding to $70 million, with continued backing from existing investors ARTIS Ventures, Stride, and ACME.
At the centre of the company’s work is AURA, which it describes as the world’s first fully automated IVF lab platform. The technology applies robotics and artificial intelligence to standardise more than 200 procedures involved in in-vitro fertilisation, an area that has long relied on manual techniques that can vary in consistency.
By automating delicate tasks such as the combination of sperm and egg, Conceivable aims to remove the unpredictability and inefficiencies that have historically shaped IVF outcomes.
“This funding validates our vision of transforming IVF through AI-powered robotic automation,” said Alan Murray, co-founder and CEO of Conceivable. “Our platform addresses the core challenges facing fertility clinics today—unpredictable success rates, capacity constraints, and accessibility barriers. This investment allows us to accelerate our bringing this groundbreaking technology to market.”
The company is currently running a 100-patient pilot study, with early pregnancy outcomes reported as positive. “Ongoing pregnancy results from the current trial are quite positive and we have 18 healthy babies from an earlier study on prototype instruments,” said Dr. Alejandro Chavez-Badiola, reproductive endocrinologist, co-founder, and Chief Medical Officer of Conceivable. “Early indications from clinical KPIs are very promising and demonstrate that robotic precision and AI-driven protocols will outperform traditional manual approaches. We are committed to delivering consistent outcomes that fertility patients deserve.”
Conceivable has set its sights on a 2026 launch in the US, supported by new partnerships with fertility networks. The firm sees its work as an answer to growing demand for IVF services, which experts predict could reach ten times the current capacity.
“The fertility industry stands at a critical inflection point where breakthrough innovation will fundamentally expand access to care,” said Alex Christ, General Partner at Advance Venture Partners. “We saw a fragmented landscape of companies building low impact, point solutions for individual IVF processes, but only Conceivable tackling the full end-to-end approach to IVF that truly pushes the industry forward. By integrating these complex steps in one system, they’ve revolutionized the IVF lab with technology, engineering, and biology at the core. Conceivable’s technology will enable the entire sector to deliver fertility care that’s more consistent, scalable, and – most importantly – within reach for the families who need it most.”
